Montana Chapter of the American College of Cardiology

AI in CV Diagnosis: From Smartwatch Screening to Faster Echo Interpretation
Two late-breaking studies presented at AHA 2026 highlight AI's potential to extend cardiovascular screening and improve diagnostic workflow, while underscoring the continued importance of clinician oversight.
ATTAIN-OSA: Orforglipron For Severe OSA in Adults With Obesity or Overweight
Once-daily oral orforglipron improved moderate to severe obstructive sleep apnea (OSA) compared with placebo in adults with obesity or overweight, based on findings from the ATTAIN-OSA trial presented at AHA 2026 and simultaneously published in JAMA.
NCDR Research at AHA 2026: OAC After LAAO; PCI and tMCS in Patients With Ischemic Cardiomyopathy
Explore key findings from two AHA 2026 abstracts using NCDR registry data.
TYDAL-TIMI 78: ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglyceride Levels
Inhibition of angiopoietin-like protein 4 (ANGPTL4) with the monoclonal antibody MAR001 significantly reduced fasting triglyceride levels at 12 weeks, based on findings from the TYDAL-TIMI 78 trial presented at AHA 2026 and simultaneously published in NEJM.
Online Exclusive | From the Member Sections | Integrating Palliative Care Into LVAD Care
Caring for a person with a left ventricular assist device (LVAD) teaches the importance of shared decision-making and the complexities of care through the end of life. Clinicians carry those memories, such as a young mother living with an LVAD and recurrent driveline infections...